BCG immunotherapy is the gold-standard treatment for non-muscle-invasive bladder cancer
at high risk of recurrence or progression. Preclinical and clinical studies have revealed that a …

Stage T1 bladder cancers invade the lamina propria of the bladder and, despite sharing
many of the genetic features of muscle-invasive bladder cancers, are classified as non …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Purpose: To characterize immune cell expression among patients with non–muscle invasive
bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG). Experimental Design …

The long-term survival of patients with advanced urothelial carcinoma (UCa) is limited
because of innate resistance to treatment. We identified elevated expression of the histone …

Bladder cancer (BCa) is the second most common genitourinary and fourth most common
cancer overall in the United States, with an estimated 81,400 newly diagnosed cases …

Introduction Seventy-five percent of bladder cancers are non-muscle invasive. The treatment
strategy includes the transurethral resection of bladder tumor (TURB) followed by …

With the mechanistic understanding of immune checkpoints and success in checkpoint
blockade using antibodies for the treatment of certain cancers, immunotherapy has become …

Cancer immunotherapy has witnessed significant advances in the past decade, however
challenges associated with immune‐related adverse effects and immunosuppressive tumor …

For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the
form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line …